Antibodies addressing PD-1 or PD-L1 are shown to be effective and safe in a variety of malignancies, including non-small cell lung carcinoma (NSCLC), renal cell carcinoma (RCC), bladder cancer, and Hodgkin’s lymphoma. This evidence concerns the gene PDCD1 and renal cell carcinoma.